Author: Ken Dropiewski

Tenaya Therapeutics Announces Pricing of Upsized Initial Public Offering

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, announced today the pricing of its underwritten, upsized initial public offering of 12,000,000 shares of its common stock at an […]

Cardinal Health completes sale of Cordis business to Hellman & Friedman

DUBLIN, Ohio, Aug. 2, 2021 /PRNewswire/ — Cardinal Health (NYSE: CAH) and Hellman & Friedman (H&F) announced today the completion of the previously announced sale of Cardinal Health’s Cordis business to H&F. The sale price of approximately $1 billion includes the buyer’s assumption of certain liabilities and the seller’s retention of certain working capital accounts. […]

Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events

– Ionis-discovered pelacarsen continues to advance as potential first new therapy for Lp(a)-driven cardiovascular disease CARLSBAD, Calif., Aug. 2, 2021 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that pelacarsen, formerly known as AKCEA-APO(a)-LRx, and licensed by Novartis (NYSE: NVS) for exclusive worldwide development and commercialization,  continues to advance in the clinic as the potential […]

UPTRAVI® (selexipag) Receives FDA Approval for Intravenous Use in Adult Patients with Pulmonary Arterial Hypertension (PAH)

New formulation allows for uninterrupted treatment for PAH patients temporarily unable to take oral therapy TITUSVILLE, N.J., July 30, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved UPTRAVI® (selexipag) injection for intravenous (IV) use for the treatment of pulmonary arterial […]

New Study Aims to Show Effectiveness of CRT-D Technology for Heart Failure Patients with Atrial Fibrillation

First Enrollments Underway for BIO-AffectDX Trial Evaluating Advanced, Two-Lead CRT-DX System LAKE OSWEGO, Ore., July 30, 2021 /PRNewswire/ — In association with Heart Rhythm 2021, BIOTRONIK today announced first enrollments in the landmark BIO-AffectDX trial, designed to evaluate clinical outcomes of cardiac resynchronization therapy (CRT) in patients with heart failure (HF) and atrial fibrillation (AF). BIO-AffectDX is a multi-center, observational study that will enroll HF […]

MindMics Announces Results from a Clinical Trial of Revolutionary Earbuds Technology — In-ear Infrasonic Hemodynography – to Achieve Cardiac Arrhythmia Assessment beyond that of ECG

Results Presented at the Heart Rhythm Society Meeting in Boston, July 30, 2021 CAMBRIDGE, Mass., Aug. 2, 2021 /PRNewswire/ – MindMics, Inc. reported results from the clinical trial of revolutionary earbuds that make use of a new technology — in-ear infrasonic hemodynography (IH) – for the monitoring of cardiac arrhythmias, resulting in insights beyond […]

Lexicon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical Update

Conference Call and Webcast at 8:00 am Eastern Time THE WOODLANDS, Texas, July 30, 2021 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2021 and provided an update on key milestones. “We remain on track to submit our New Drug Application […]

Windtree Appoints Randall White, Ph.D., as Vice President, Clinical Program Management

WARRINGTON, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced the appointment of Randall White, Ph.D., as Vice President, Clinical Program Management, reporting to Steve Simonson, M.D., […]

Artio Medical Successfully Completes Enrollment of First-in-Human Trial Investigating the Amplifi™ Vein Dilation System

Novel vein dilation system aims to improve vascular access for hemodialysis patients Prairie Village, KS – July 14, 2021 – Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular, neurovascular, and structural heart markets, announced today it has completed enrollment in its first-in-human study evaluating the […]